{
  "id": 5916,
  "text": "J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-5.(编辑: 王雪萍)",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-\n\n<question>: ",
  "ChatGPT_response_0": "根据研究结果显示，这项研究对未经治疗的宫颈癌患者可能并不适用相同的影响。因为该研究主要着眼于先前接受过治疗并出现复发或转移的宫颈癌患者，对于未经治疗的患者，可能需要进行更多的研究和临床试验来确定该治疗方法的有效性和安全性。因此，在考虑是否适用于未经治疗的宫颈癌患者时，需谨慎评估现有数据以及患者的具体情况，最好在专业医生的指导下作出决定。",
  "query": "这项研究的结果对于未经治疗的宫颈癌患者是否具有同样的影响呢？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 这项研究的结果对于未经治疗的宫颈癌患者是否具有同样的影响呢？\n\n<reference text>: J Clin Oncol, 2015, 33 ( 19): 2129 - 2135.DOI: 10.1200 / JCO.2014.58.4391.[74] Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer ( innovaTV 204 / GOG-3023 / ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study [ J ] .Lancet Oncol, 2021, 22 ( 5): 609 - 619.DOI: 10.1016 / S1470-2045 (21)00056-5.(编辑: 王雪萍)\n\n<reply>: ",
  "response": "根据研究结果显示，这项研究对未经治疗的宫颈癌患者可能并不适用相同的影响。因为该研究主要着眼于先前接受过治疗并出现复发或转移的宫颈癌患者，对于未经治疗的患者，可能需要进行更多的研究和临床试验来确定该治疗方法的有效性和安全性。因此，在考虑是否适用于未经治疗的宫颈癌患者时，需谨慎评估现有数据以及患者的具体情况，最好在专业医生的指导下作出决定。"
}